Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia.
Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia.
复制标题
DOI：
10.3892/mco.2016.864
复制
发表时间：
2016-07
影响因子：
1.2
通讯作者：
Nomura S
中科院分区：
文献类型：
--
作者：
Azuma Y;Nakaya A;Hotta M;Fujita S;Tsubokura Y;Yoshimura H;Satake A;Ishii K;Ito T;Nomura S
吉妥珠单抗（GO）是一种重组人源化免疫球蛋白G4抗分化簇（CD）33单克隆抗体，与天然强效抗生素N-乙酰基-γ加利车霉素二甲基酰肼偶联。它已被引入用于治疗急性早幼粒细胞白血病（APL），因为大量的CD 33通常表达在APL细胞表面。本研究报告了两例突出的弥散性血管内凝血（DIC），这是短暂的观察后，与复发性/难治性APL GO治疗。关于GO后发生DIC的信息非常有限，其机制仍有待阐明。在本研究中，重组人可溶性血栓调节蛋白用于DIC治疗，患者迅速恢复。由于DIC是与GO治疗相关的最严重的不良事件，因此需要阐明其机制并建立治疗策略。
Gemtuzumab ozogamicin (GO) is a recombinant humanized immunoglobulin G4 anti-cluster of differentiation (CD)33 monoclonal antibody conjugated to N-acetyl-γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of acute promyelocytic leukemia (APL), since large quantities of CD33 are commonly expressed on the surface of APL cells. The present study reported two cases with prominent disseminated intravascular coagulation (DIC), which was transiently observed following treatment with GO with relapsed/refractory APL. Very limited information exists regarding DIC occurring following GO, and its mechanism remains to be elucidated. In the present study, recombinant human soluble thrombomodulin was used for DIC treatment, and the patients recovered promptly. Since DIC is the most serious adverse event associated with GO treatment, elucidation of its mechanism and establishment of a treatment strategy are warranted.